Lhasa Limited shared knowledge shared progress

AstraZeneca Becomes the First Lhasa Member to Realise the Benefits of Mirabilis through SaaS

Date: 04 October 2018

Time: 11:00 to 19:00

Mirabilis - software that can help experts assess and predict the likelihood for the potential carryover of impurities.

Lhasa Limited, an educational charity which creates state-of-the-art in silico prediction and database systems, today announced that AstraZeneca has become the first organisation to adopt Mirabilis through Software as a Service (SaaS).

Requiring no customer installation, and no additional servers or other expensive hardware, Mirabilis through SaaS has been made available quickly to AstraZeneca, providing them with rapid access to this unique solution, without compromising the confidentiality of their own proprietary information. The Mirabilis SaaS offering uses the Amazon Web Services (AWS) cloud platform, which is widely used by the pharmaceutical industry because of its exceptional security, scale and global reach. 

Mirabilis uses an industry-standardised approach to provide a scientifically robust calculation of purge factors of potentially mutagenic impurities in a synthetic route. Crucially, it can be used to satisfy ICH M7 Control Option 4 by producing an estimated purge factor for removal of an impurity by a synthetic process. Based on the principles established by Teasdale et al.1,2, Mirabilis is the result of collaboration between Lhasa Limited and a number of pharmaceutical companies (including AstraZeneca), is built on expert knowledge and is semi-automated to improve the efficiency of purge analysis.

Dr. Andrew Teasdale, Senior Principal Scientist at AstraZeneca said: “Being able to implement Mirabilis efficiently and effectively without the need for new hardware is a huge positive in allowing us to leverage this important tool”.

Dr, James Willans, Chief Technology Officer at Lhasa Limited, said: “I am delighted that AstraZeneca are adopting Mirabilis SaaS and are able to realise the business value of Mirabilis without being concerned with software installation and maintenance. AstraZeneca's adoption of Mirabilis SaaS is a significant milestone in Lhasa's SaaS journey and ensuring that our best-in-class solutions are instantly available to our members”.

For more information on how Lhasa Software as a Service can streamline your impurity qualification process please contact info@lhasalimited.org or call +44 113 394 6020.

 

  1. Teasdale et al. (2010) ‘A Tool for the Semiquantitative Assessment of Potentially Genotoxic Impurity (PGI) Carryover into API Using Physicochemical Parameters and Process Conditions’, Organic Process Research & Development, vol. 14, pp 943-945.
  2. Teasdale et al. (2013) ‘Risk Assessment of Genotoxic Impurities in New Chemical Entities: Strategies To Demonstrate Control’, Organic Process Research & Development, vol. 17, pp 221-230. 
  • Summary:

    Lhasa Limited, an educational charity which creates state-of-the-art in silico prediction and database systems, today announced that AstraZeneca has become the first organisation to adopt Mirabilis through Software as a Service (SaaS).

  • Categories:
    • Collaborative Projects
    • Mirabilis

© 2018 Lhasa Limited | Registered office: Granary Wharf House, 2 Canal Wharf, Leeds, LS11 5PS, UK Tel: +44 (0)113 394 6020
VAT number 396 8737 77 | Lhasa Limited is registered as a charity (290866)| Company Registration Number 01765239 (England and Wales).

Thanks to QuestionPro's generosity, we now have survey software that powers our data intelligence.

IP: 54.227.31.145 | Group: ###groupid###